Top Markets
#1 NKN NKN +176.99%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +28.77%
#5 Saakuru Saakuru +25.09%
#6 Bedrock Bedrock +16.99%
#7 Particle Network Particle Network +15.34%
#8 TronBank TronBank +13.85%
#9 Janction Janction +13.83%
#10 Arcblock Arcblock +13.66%
Coin of the day
NKN NKN
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classifica tra le azioni #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prezzo delle azioni
$208.57
Capitalizzazione di mercato
$368.78B
Variazione (1 giorno)
0.68%
Variazione (1 anno)
3.61%
Paese
US
Scambia AbbVie Inc. (ABBV)

Categoria

Healthcare
Storico del rendimento da dividendi per AbbVie Inc. (ABBV)
Il rendimento da dividendi (TTM) di AbbVie Inc. (simbolo azionario: ABBV) al 2024-12-31 è: 3.51%
Rendimento medio negli ultimi 5 anni: 3.52%
Storico del rendimento da dividendi per AbbVie Inc. (ABBV) da 2009 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
2026 (TTM) 3.03% 5.57%
2025 2.87% -18.23%
2024 3.51% -8.83%
2023 3.85% 9.69%
2022 3.51% -9.07%
2021 3.86% -10.65%
2020 4.32% -10.93%
2019 4.85% 23.41%
2018 3.93% 47.74%
2017 2.66% -27.32%
2016 3.66% 7.02%
2015 3.42% 34.12%
2014 2.55% -16.12%
2013 3.04% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
0.63%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
1.64%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.15%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
3.05%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.84%
US